Drug recall · January 23, 2019
Olmesartan Medoxomil and Hydrochlorothiazide Tablets recall
Why: Failed dissolution specifications
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 40 mg/25 mg, packaged in a) 30-count bottle (NDC 0093-7617-56), b) 90-count bottle (NDC 0093-7617-98), Rx only, Manufactured In Israel By: Teva Pharmaceutical, IND. LTD., Jerusalem, 9777402, Israel, Manufactured For: Teva Pharmaceutical USA, INC., North Wales, PA 19454
- Lots / codes
Lot #: a) 49O005, 49O006, 49O007, 49O010, Exp 02/2019; b) 49O005, 49O009, 49O010, Exp 02/2019
- Quantity
- 181,456 bottles
- Company
- Teva Pharmaceuticals USA, North Wales, PA
- Distribution
- U.S.A. nationwide
- Initiated
- December 19, 2018 · Voluntary: Firm initiated
- Classified
- January 16, 2019
- Reported
- January 23, 2019
- Ended
- August 31, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hydrochlorothiazide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.